Results 1 to 10 of about 56,503 (261)

Pneumococcal vaccines in China. [PDF]

Hum Vaccin Immunother
Invasive pneumococcal disease (IPD) is a serious global public health problem and the leading cause of morbidity and mortality in children and adults in China. Thus, developing and administering pneumococcal vaccines are important for disease prevention.
Wang S, Li B, Chen Q, Wang C, Wang B, Ye Q, Xu Y.   +6 more
europepmc   +4 more sources

Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies [PDF]

Vaccines, 2021
The importance of Streptococcus pneumoniae has been well established. These bacteria can colonize infants and adults without symptoms, but in some cases can spread, invade other tissues and cause disease with high morbidity and mortality. The development
Giuliana S. Oliveira, Maria Leonor S. Oliveira, Eliane N. Miyaji, Tasson C. Rodrigues   +3 more
doaj   +2 more sources

Pneumococcal Vaccines

Microbiology Spectrum, 2019
Streptococcus pneumoniae is a Gram-Positive pathogen that is a major causative agent of pneumonia, otitis media, sepsis and meningitis across the world.
D. E. Briles, J. C. Paton, R. Mukerji, E. Swiatlo, M. J. Crain   +4 more
doaj   +4 more sources

New Vaccines for the Prevention of Pneumococcal Infections

Emerging Infectious Diseases, 1996
Streptococcus pneumoniae is a major cause of acute otitis media, pneumonia, bacteremia, and meningitis. Because in recent years antibiotic-resistant pneumococcal strains have been emerging throughout the world, vaccination against pneumococcal infections
Helena Käyhty, Juhani Eskola
doaj   +2 more sources

Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death

Vaccines, 2020
Various studies indicate that vaccination, especially with pneumococcal vaccines, protects against symptomatic cases of SARS-CoV-2 infection and death.
Robert Root-Bernstein
doaj   +2 more sources

Uptake of Pneumococcal Vaccines Among U.S. Adults After 2022 Update to Recommendations [PDF]

AJPM Focus
Introduction: Updated recommendations for adult pneumococcal vaccination in the U.S. (publication date: January 27, 2022) incorporated 2 new vaccines (15- and 20-valent pneumococcal conjugate vaccines), removed 13-valent pneumococcal conjugate vaccine ...
Ahuva Averin, MPP, Jeffrey Vietri, PhD, Adriano Arguedas Mohs, MD, Sarah J. Willis, PhD, MPH, Alexander Lonshteyn, PhD, Derek Weycker, PhD   +5 more
doaj   +2 more sources

Bacterium-like Particles from Corynebacterium pseudodiphtheriticum as Mucosal Adjuvant for the Development of Pneumococcal Vaccines [PDF]

Vaccines
Previously, it was shown that intranasally (i.n.) administered Corynebacterium pseudodiphtheriticum 090104 (Cp) or CP-derived bacterium-like particles (BLPs) improve the immunogenicity of the pneumococcal conjugate vaccine (PCV).
Ramiro Ortiz Moyano, Fernanda Raya Tonetti, Mariano Elean, Yoshiya Imamura, Kohtaro Fukuyama, Yoshihito Suda, Vyacheslav Melnikov, Alexander Suvorov, María Guadalupe Vizoso-Pinto, Haruki Kitazawa, Julio Villena   +10 more
doaj   +2 more sources

Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases [PDF]

Human Vaccines & Immunotherapeutics, 2019
Streptococcus pneumoniae causes pneumonia, meningitis, otitis media, and bacteremia. The mortality and morbidity of invasive pneumococcal disease are high among adults aged >65 years or those with underlying chronic or immunosuppressive conditions.
Koji Kuronuma, Hiroki Takahashi
doaj   +2 more sources

Effectiveness of pneumococcal vaccine [PDF]

The Lancet, 1998
Åke Örtqvist, Jonas Hedlund, Mats Kalin   +2 more
openalex   +4 more sources

Pneumococcal vaccine [PDF]

Journal of Medical Microbiology, 1996
Streptococcus pneumoniae, commonly termed the pneumococcus, is a major pediatric pathogen both in developed and developing countries. Despite the availability of multiple antimicrobials to which this organism is susceptible, it continues to cause significant morbidity and mortality. Recognition of the limitations of antimicrobial therapy in controlling
G, Peter, J O, Klein
openaire   +4 more sources